When new drugs are approved, the marketing authorization holders often have to commit themselves to perform additional post-authorization studies. These studies have a different set up. Most countries have adjusted the regulations for studies where the drug is commercially available; although there is no "one fits all" concept.
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
Our Embedded Solutions™ model helps clients execute their product portfolios more efficiently, with greater control, standardization, consistency,…
THE INSIGHT SERIES: Can you use the same outsourcing methodologies for post-marketing studies as pre-approval research? - Part 4
As the number of preferred provider relationships grow and become more sophisticated, budget grids and assumptions must align with the needs of…